Oncolytics Biotech Inc. (ONCYF) Downgraded to Sell at ValuEngine
ValuEngine cut shares of Oncolytics Biotech Inc. (OTCMKTS:ONCYF) from a hold rating to a sell rating in a research note published on Friday morning.
Oncolytics Biotech (OTCMKTS:ONCYF) traded up 0.75% during midday trading on Friday, hitting $0.41. The company had a trading volume of 33,326 shares. Oncolytics Biotech has a 52-week low of $0.14 and a 52-week high of $0.85. The stock has a 50 day moving average of $0.40 and a 200 day moving average of $0.46. The firm’s market cap is $57.16 million.
About Oncolytics Biotech
Oncolytics Biotech Inc is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company’s clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials.
Receive News & Stock Ratings for Oncolytics Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech Inc. and related stocks with our FREE daily email newsletter.